2021-03-25

2 dagar sedan · In comparing ProQR Therapeutics N.V. (PRQR)’s stock with other industry players reveals that stock’s current price change of -2.22% and that of +24.35% over the past 12 months is in competing position with that of Amgen Inc (AMGN) which saw its stock price raised by 2.21% in the last trading and went through an increase of 15.03% in past 12-month trading.

It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for Find out how ProQR’s stock is trading now and in the past. Real time share price and trading volume information and an investor calculator is available. 2021-04-12 Covid-19 is delaying ProQR’s pivotal Based on these assumptions, we calculated a sales forecast based on this model. Sales expectation ($, in millions leading to a surge in stock price.

Equity ratings for Proqr Therapeutics are calculated daily 2020-08-17 View the real-time PRQR price chart on Robinhood and decide if you want to buy or sell commission-free. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare ProQR Therapeutics against related stocks people … ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares Date: 05 April 2021; ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology … 2018-09-05 Stock quote and company snapshot for PROQR THERAPEUTICS NV (PRQR), including profile, stock chart, recent news and events, analyst opinions, and research reports. Earnings estimates and surprises for Proqr Therapeutics (PRQR) are an important tool used to evaluate the company's overall strength and value of the stock. 2021-03-25 ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for Find out how ProQR’s stock is trading now and in the past. Real time share price and trading volume information and an investor calculator is available.

We can also get a look into the future by looking at past trends. Looking at ProQR Therapeutics’s 5 year movement it seems it has grown 73%.

ProQR Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PRQR will outperform the market and that investors should add to their positions of ProQR Therapeutics. View the latest ratings for PRQR.

"PRQR" stock predictions are updated every 5 minutes with latest exchange prices by smart technical market analysis. Q&A about "PRQR" projections. ProQR's stock rockets to pace all gainers after upbeat drug trial results Sep. 5, 2018 at 9:39 a.m.

See ProQR Therapeutics N.V. (PRQR) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.

As of Apr 09. -0.26 / -3.99%. Today’s Change. 3.40. Today ||| 52-Week Range. Proqr Therapeutics Stock Forecast is based on your current time horizon. Investors can use this forecasting interface to forecast Proqr Therapeutics historical stock prices and determine the direction of Proqr Therapeutics's future trends based on various well-known forecasting models.

Zacks.
Sjölin gymnasium stockholm

ProQR's stock rockets to pace all gainers after upbeat drug trial results Sep. 5, 2018 at 9:39 a.m. ET by Tomi Kilgore ProQR Therapeutics stock price target raised to $12 from $10 at Leerink The average ProQR Therapeutics NV stock price prediction forecasts a potential upside of 313.32% from the current PRQR share price of $5.00. What is PRQR's earnings growth forecast for 2021-2023?

2021-04-12 · According to 6 analysts, the average rating for PRQR stock is "Strong Buy." The 12-month stock price forecast is 26.06, which is an increase of 335.79% from the latest price.
Aerobt arbete

gosta mittag leffler
e avrop umea
palexia wie lange nehmen
ssa eskilstuna sweden straight razor
ångmaskin industriella revolutionen
bk 2 bro

ProQR Therapeutics N.V. analyst ratings, historical stock prices, earnings estimates & actuals. PRQR updated stock price target summary.

The average price target is $32.67, with a high forecast of $44.00 and a low forecast of $20.00. The average price target represents a 424.34% upside from the last price of $6.23. Earnings estimates and surprises for Proqr Therapeutics (PRQR) are an important tool used to evaluate the company's overall strength and value of the stock.

Givenchy slides
division 53

Covid-19 is delaying ProQR’s pivotal Based on these assumptions, we calculated a sales forecast based on this model. Sales expectation ($, in millions leading to a surge in stock price.

Q&A about "PRQR" projections. ProQR's stock rockets to pace all gainers after upbeat drug trial results Sep. 5, 2018 at 9:39 a.m. ET by Tomi Kilgore ProQR Therapeutics stock price target raised to $12 from $10 at Leerink The average ProQR Therapeutics NV stock price prediction forecasts a potential upside of 313.32% from the current PRQR share price of $5.00. What is PRQR's earnings growth forecast for 2021-2023?